myelofibrosis - Cleveland Clinic

August 22, 2025/Cancer/News & Insight

New Essential Thrombocythemia Treatment Appears to Address Underlying Disease

Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities

April 7, 2025/Cancer/News & Insight

Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

June 13, 2023/Cancer/Research

Luspatercept Shows Promise as Treatment for Anemia in Patients With Myelofibrosis

Approach resulted in transfusion independence and durable anemia response

22-CNR-3344410-CQD-Hero-650×450 Dr Gerds Momentum trial

December 9, 2022/Cancer/Research

Sustained Response Observed in MOMENTUM Trial of Patients with Myelofibrosis

Study matches momelotinib against danazol

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

March 23, 2022/Cancer/Blood Cancers

Experimental Drug Shows Promise for Alleviating Myelofibrosis-Associated Anemia

Momelotinib, a new JAK inhibitor, inches closer to market approval

January 7, 2021/Cancer/Blood Cancers

Pacritinib Moves Closer to FDA Approval for Myelofibrosis

Dose-finding trial adds to evidence of efficacy

December 9, 2019/Cancer/Research

Treatment for Myelofibrosis-Associated Anemia on the Horizon

Interim results of phase 2 trial are promising

September 25, 2018/Cancer/Research

Try Ruxolitinib Again When Effectiveness Wanes in Myelofibrosis

Second (or third) time’s a charm in reducing splenomegaly and other symptoms

April 5, 2018/Cancer/Research

How a Myelofibrosis Drug PERSISTed Through an FDA Hold

Final results of PERSIST-2 confirm benefit; PAC203 enrolling

Tag: myelofibrosis